Streetbeat News

Stock Prices

MAR

Marriott International forecasts its Q1 adjusted EPS to be between $2.12 and $2.19, below the $2.3 estimate. For FY24, the adjusted EPS is projected to be between $9.18 and $9.52, also below the $9.69 estimate. The company anticipates worldwide RevPAR growth of 4% to 5% for Q1 and 3% to 5% for the full year 2024.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:12 pm

LCII

LCI Industries (LCII) reported a Q4 EPS of $(0.09), missing the analyst consensus estimate of $0.18 by 150%. Year-over-year, this represents an 86.76% decrease in losses per share from $(0.68). Quarterly sales were $837.54M, slightly missing the estimate of $838.27M by 0.09%, and marking a 6.35% decrease from the previous year's $894.35M.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:11 pm

LIAN

LianBio has concluded its strategic review and decided to wind down operations, including selling its pipeline assets, delisting its ADSs, and reducing its workforce. The board has declared a special dividend of $4.80 per share.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:09 pm

DDOG

Datadog shares are trading lower following the company's announcement of Q1 and FY24 earnings per share (EPS) guidance that fell below analyst estimates.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:07 pm

BRKR

Bruker Corporation (NASDAQ:BRKR) reported Q4 adjusted EPS of $0.70, surpassing the $0.68 estimate, and sales of $854.50M, exceeding the $807.49M estimate. This represents a 5.41% decrease in EPS and a 20.62% increase in sales year-over-year.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:05 pm

INCY

Incyte (NASDAQ:INCY) reported Q4 adjusted earnings of $1.06 per share, missing the consensus estimate of $1.16 by 8.62%. However, their quarterly sales of $1.01 billion exceeded the $1.00 billion estimate by 1.30%, marking a 9.31% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:05 pm

SHOP

Shopify anticipates its Q1 revenue to increase at a low-twenties percentage rate compared to Q4, with an expected gross margin improvement of approximately 150 basis points over Q4.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:05 pm

BIIB

Biogen (NASDAQ:BIIB) reported Q4 earnings of $2.95 per share, missing the consensus estimate of $3.18, marking a 27.16% decrease from last year. Quarterly sales were $2.39B, also below the $2.46B estimate, representing a 6.21% year-over-year decline.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:05 pm

MAR

Marriott International (NASDAQ:MAR) reported Q4 adjusted earnings per share of $3.57, surpassing the $2.12 estimate, marking an 82.14% increase from last year. However, their quarterly sales of $6.09B fell short of the $6.20B estimate, a 2.90% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:04 pm

INMD

InMode (NASDAQ:INMD) reported Q4 adjusted EPS of $0.71, surpassing the $0.67 estimate, and sales of $126.78M, exceeding the $125.04M estimate. However, this reflects a decrease from the previous year's earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:03 pm